Misghina T. Weldegiorgis
Misghina Weldegiorgis is an epidemiologist at The George Institute for Global Health at the University of Oxford.
His current work focuses on investigating the effects of social and clinical risk factors, such as diabetes, obesity, and blood pressure, on vascular and, other, disease.
Misghina earned his BSc degree in Pharmacy from the University of Asmara, MSc degree in Pharmaco-epidemiology from Utrecht University, and Ph.D. degree from the University of Groningen.
Specialties: Evaluation of renal endpoints for clinical trials, pharmacogenetics, longitudinal analysis, multivariate analysis, chronic kidney disease, diabetic nephropathy, and cardiovascular diseases.
Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.
Weldegiorgis M. et al, (2018), Am j kidney dis, 71, 91 - 101
Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
Weldegiorgis M. et al, (2017), Clinical journal of the american society of nephrology : cjasn, 12, 1595 - 1600
Renal end points in clinical trials of kidney disease.
Weldegiorgis M. et al, (2015), Curr opin nephrol hypertens, 24, 284 - 289
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ. et al, (2014), Am j kidney dis, 63, 244 - 250
Change in albuminuria and risk of renal and cardiovascular outcomes: natural variation should be taken into account
Smith M. et al, Kidney international reports